Viage Therapeutics is a biotech company that develops therapeutics that stimulates the central nervous system via the gut-brain axis.
Viage Therapeutics has raised $10.0M in total funding. The most recent round was Seed. The last funding was announced in January 2022.
Viage Therapeutics's investors include ANRI, Kyoto University Innovation Capital, Remiges Ventures, Miyako Capital, Zhongze.
Viage Therapeutics is headquartered in San Francisco, United States.
Viage Therapeutics is a biotech company that develops therapeutics that stimulates the central nervous system via the gut-brain axis.
Viage Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Viage Therapeutics — Funding & Investors." VCBacked, January 6, 2022, https://www.vcbacked.co/company/viage-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Viage Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/viage-therapeutics
{{cite web |title=Viage Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/viage-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated